Key information

Recruitment dates:

18 February, 2019 to 28 February, 2021
(Trial recruitment open)

Trial phase:

phase II

Treatment stage:


Trial investigator:

 Rebecca Kristeleit 

Contact: Laura Hughes 0207 679 9284

University College London Hospital


Trial website:


ovarian gynaecological clear cell cancer



Clinical trial locations

Location list

Contact: Dr. Rebecca Kristeleit
University College London, Gower Street, London
Western General Hospital
Edinburgh Cancer Centre


PEACOCC will treat women with clear cell cancer of gynaecological tract (ovary, fallopian tube, uterus, cervix, vagina or vulva) who have already received at least one course of chemotherapy but their cancer is growing and needs further treatment. The study will address whether these women may benefit from treatment with a drug called pembrolizumab, which is a type of immunotherapy drug. Pembrolizumab is designed to stimulate the body’s immune system to “see” and fight the cancer cells.

About the trial

All women in the study will receive the study drug, pembrolizumab, for up to 2 years or until their study doctor thinks the study drug is no longer helping to control the cancer or if unacceptable side effects are seen or if the woman wishes to stop treatment.

Some women may also be suitable for a possible retreatment period with pembrolizumab for up to 1 year, if the cancer starts growing again.

Women will attend clinic as an outpatient every 3 weeks for treatment. The study drug pembrolizumab is given into a vein in the arm through a needle (intravenously) over 30 minutes once every 3 weeks (one treatment cycle). 

Who can take part?

This trial is for women that have recurrence of ovarian clear cell cancer (or clear cell cancer of the gynaecological tract such as ovary, fallopian tube, uterus, cervix, vagina or vulva) that is growing and needs further treatment. 

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.